Cypress Asset Management’s Thermo Fisher Scientific TMO Stock Holding History

Cypress Asset Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.65M	Hold	2,852	–	–	0.36%	57
2025 Q3	$1.38M	Sell	2,852 -41	-1%	-$19.1K	0.31%	63
2025 Q2	$1.17M	Sell	2,893 -10	-0.3%	-$4.18K	0.28%	63
2025 Q1	$1.44M	Buy	2,903 +6	+0.2%	+$3.25K	0.39%	56
2024 Q4	$1.53M	Sell	2,897 -47	-2%	-$25.8K	0.38%	58
2024 Q3	$1.82M	Buy	2,944 +58	+2%	+$34.3K	0.45%	54
2024 Q2	$1.63M	Hold	2,886	–	–	0.42%	55
2024 Q1	$1.7M	Buy	2,886 +254	+10%	+$143K	0.46%	57
2023 Q4	$1.4M	Sell	2,632 -11	-0.4%	-$5.32K	0.42%	60
2023 Q3	$1.34M	Buy	2,643 +40	+2%	+$21.3K	0.45%	59
2023 Q2	$1.38M	Buy	2,603 +112	+4%	+$60.4K	0.44%	59
2023 Q1	$1.44M	Hold	2,491	–	–	0.5%	60
2022 Q4	$1.37M	Hold	2,491	–	–	0.5%	61
2022 Q3	$1.26M	Hold	2,491	–	–	0.48%	61
2022 Q2	$1.35M	Hold	2,491	–	–	0.48%	63
2022 Q1	$1.47M	Sell	2,491 -1,197	-32%	-$688K	0.43%	68
2021 Q4	$2.46M	Sell	3,688 -50	-1%	-$31.2K	0.59%	57
2021 Q3	$2.14M	Hold	3,738	–	–	0.55%	59
2021 Q2	$1.89M	Hold	3,738	–	–	0.48%	65
2021 Q1	$1.71M	Sell	3,738 -128	-3%	-$61.1K	0.47%	65
2020 Q4	$1.8M	Buy	3,866 +17	+0.4%	+$7.97K	0.5%	66
2020 Q3	$1.7M	Buy	3,849 +109	+3%	+$45K	0.53%	61
2020 Q2	$1.35M	Sell	3,740 -20	-0.5%	-$6.7K	0.45%	70
2020 Q1	$1.07M	Hold	3,760	–	–	0.46%	69
2019 Q4	$1.22M	Hold	3,760	–	–	0.42%	80
2019 Q3	$1.09M	Sell	3,760 -25	-0.7%	-$7.16K	0.38%	82
2019 Q2	$1.11M	Sell	3,785 -25	-0.7%	-$6.89K	0.38%	83
2019 Q1	$1.04M	Hold	3,810	–	–	0.35%	85
2018 Q4	$853K	Hold	3,810	–	–	0.32%	86
2018 Q3	$930K	Buy	3,810 +25	+0.7%	+$5.75K	0.27%	93
2018 Q2	$784K	Hold	3,785	–	–	0.23%	102
2018 Q1	$781K	Sell	3,785 -200	-5%	-$42K	0.23%	100
2017 Q4	$757K	Sell	3,985 -100	-2%	-$19.2K	0.16%	110
2017 Q3	$773K	Hold	4,085	–	–	0.17%	111
2017 Q2	$713K	Sell	4,085 -125	-3%	-$21K	0.15%	115
2017 Q1	$647K	Sell	4,210 -275	-6%	-$42K	0.12%	133
2016 Q4	$633K	Hold	4,485	–	–	0.12%	133
2016 Q3	$713K	Hold	4,485	–	–	0.14%	126
2016 Q2	$663K	Sell	4,485 -10	-0.2%	-$1.48K	0.13%	131
2016 Q1	$636K	Buy	4,495 +430	+11%	+$57.6K	0.13%	127
2015 Q4	$577K	Buy	4,065 +40	+1%	+$5.33K	0.12%	131
2015 Q3	$492K	Buy	4,025 +150	+4%	+$19.5K	0.1%	132
2015 Q2	$503K	Buy	3,875 +275	+8%	+$35.9K	0.09%	136
2015 Q1	$484K	Buy	+3,600	New	+$464K	0.09%	136

Other funds holding TMO

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cypress Asset Management's TMO Position: Q4 2025 in Review

Cypress Asset Management held its Thermo Fisher Scientific (TMO) position steady in Q4 2025 at 2,852 shares worth $1.65M. The position accounts for 0.36% of the portfolio, ranked #57.

Cypress Asset Management first reported a position in TMO in Q1 2015 and has held it in 44 quarters since. The position peaked at $2.46M in Q4 2021. 2,699 funds tracked by Wall St. Rank hold TMO as of Q4 2025.

Cypress Asset Management held 2,852 shares of Thermo Fisher Scientific worth $1.65M as of Q4 2025.
Cypress Asset Management left its Thermo Fisher Scientific share count unchanged in Q4 2025.
Thermo Fisher Scientific made up 0.36% of Cypress Asset Management's portfolio in Q4 2025, its #57 holding.
Cypress Asset Management first reported a position in Thermo Fisher Scientific in Q1 2015 and has held it in 44 quarters since.
Cypress Asset Management's Thermo Fisher Scientific position peaked at $2.46M in Q4 2021.
2,699 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2025.

Based on Cypress Asset Management's 13F filing for Q4 2025, filed 29 Jan 2026.